Pharma BD Deal Intelligence
A $1.1B all-cash acquisition that gave Novo Nordisk etavopivat, an oral pyruvate kinase-R activator for sickle cell disease. The bet paid off in April 2026 when phase 3 HIBISCUS data hit both co-primary endpoints—27% fewer vaso-occlusive crises and hemoglobin response in 48.7% of patients—positioning it as the first PKR activator to succeed in a pivotal SCD trial.
Novo Nordisk has entered into an agreement to acquire Forma Therapeutics for $1.1 billion, at $20 per share in cash representing a total equity value of…
Novo Nordisk has concluded the acquisition of Forma Therapeutics for $20 for each share in cash or a deal totalling $1.1bn. With the conclusion of the merger,…
Etavopivat met both co-primary endpoints in phase 3 HIBISCUS: 27% reduction in VOC events and superior haemoglobin response vs placebo in 385 people with SCD;…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Novo Nordisk acquired Forma Therapeutics in 2022 (closed 9 Dec 2022) for approximately USD 1.1bn all-cash (USD 20/share) to gain etavopivat (FT-4202), an oral once-daily pyruvate kinase-R (PKR) activator for sickle cell disease (SCD), expanding Novo Nordisk's rare blood disorders pipeline. The thesis was validated in April 2026: on 20 April 2026 Novo Nordisk reported that the pivotal phase 3 HIBISCUS trial (52 weeks, etavopivat 400 mg once-daily vs placebo, n=385, ages 12+) met both co-primary endpoints — a 27% reduction in vaso-occlusive crisis events (median time to first VOC 38.4 vs 20.9 weeks) and a haemoglobin response of >1 g/dL at 24 weeks in 48.7% of treated patients vs 7.2% on placebo. Etavopivat is the first PKR activator to succeed in a phase 3 SCD trial, and Novo Nordisk plans its first regulatory submission in the second half of 2026.
100K US cases/yr · $4.5B US Sickle Cell Disease Market · ~300K Annual US SCD-Related ED Visits
Sickle cell disease is a group of inherited red blood cell disorders affecting approximately 100,000 Americans, predominantly of African descent. Etavopivat (FT-4202) is a next-generation oral pyruvate kinase-R (PKR) activator that improves red blood cell health by increasing ATP and 2,3-DPG levels, reducing sickling. Novo Nordisk acquired Forma for $1.1B to expand its rare blood disorders pipeline.
The SCD market is transforming with Casgevy (exa-cel, Vertex/CRISPR) and Lyfgenia (lovo-cel, bluebird) gene therapies approved in 2023. Hydroxyurea remains standard of care. Oxbryta (voxelotor, Pfizer/GBT) was withdrawn in 2023. Adakveo (crizanlizumab) showed limited efficacy. Etavopivat offers an oral, daily alternative mechanism that may complement existing therapies.
Novo Nordisk acquired Forma to gain etavopivat (PKR activator) for sickle cell disease.
Novo Nordisk reported topline phase 3 HIBISCUS results: etavopivat (the Forma lead asset) achieved a 27% reduction in vaso-occlusive crisis events and a haemoglobin response >1 g/dL at 24 weeks in 48.7% of patients vs 7.2% placebo (n=385, 52 weeks, 400 mg QD). First PKR activator to hit phase 3 in SCD; first regulatory submission planned 2H 2026 — validating the 2022 $1.1B acquisition.
Etavopivat integrated into Novo rare blood disorders pipeline. Complementing hemophilia portfolio.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Novo Nordisk A/S / Forma Therapeutics Holdings Inc. (this deal) | 2022 | $1.1B | 68 |
| Novo Nordisk A/S / Emisphere Technologies | 2020 | $1.4B | 90 |
| Novo Nordisk A/S / Dicerna Pharmaceuticals, Inc. | 2019 | $3.3B | 88 |
| Novo Nordisk A/S / Vivtex Inc. | 2026 | $2.1B | 69 |
| Novo Nordisk A/S / Dicerna Pharmaceuticals, Inc. | 2021 | $3.3B | 68 |
| Novo Nordisk A/S / Inversago Pharma | 2023 | $1.1B | 61 |
| Novo Nordisk A/S / Forma Therapeutics Holdings Inc. | 2022 | $1.1B | 58 |
← Browse all deals · How we score deals
More: 2022 deals · Novo Nordisk A/S deals · Hematology deals